GrippeCanadaV3, Main, Exploration, bibRecord, 000169

A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.

Identifieur interne : 000169 ( Main/Exploration ); précédent : 000168; suivant : 000170

A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.

Auteurs : Danuta M. Skowronski ; Catharine Chambers ; Suzana Sabaiduc ; Gaston De Serres ; Anne-Luise Winter ; James A. Dickinson ; Mel Krajden ; Jonathan B. Gubbay ; Steven J. Drews ; Christine Martineau ; Alireza Eshaghi ; Trijntje L. Kwindt ; Nathalie Bastien ; Yan Li

Source :

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [ 1537-6591 ] ; 2016.

RBID : pubmed:27025838

Descripteurs français

KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Canada (épidémiologie), Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine (), Grippe humaine (immunologie), Grippe humaine (virologie), Grippe humaine (épidémiologie), Génome viral (génétique), Humains, Jeune adulte, Mâle, Nourrisson, Sujet âgé, Surveillance sentinelle, Vaccins antigrippaux (immunologie), Virus de la grippe A (génétique), Virus de la grippe A (immunologie), Virus influenza B (génétique), Virus influenza B (immunologie).
MESH :
- génétique : Génome viral, Virus de la grippe A, Virus influenza B.
- immunologie : Grippe humaine, Vaccins antigrippaux, Virus de la grippe A, Virus influenza B.
- virologie : Grippe humaine.
- épidémiologie : Canada, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine, Humains, Jeune adulte, Mâle, Nourrisson, Sujet âgé, Surveillance sentinelle.

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Canada (epidemiology), Child, Child, Preschool, Female, Genome, Viral (genetics), Humans, Infant, Influenza A virus (genetics), Influenza A virus (immunology), Influenza B virus (genetics), Influenza B virus (immunology), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Male, Middle Aged, Sentinel Surveillance, Young Adult.
MESH :
- chemical , immunology : Influenza Vaccines.
- epidemiology : Canada, Influenza, Human.
- genetics : Genome, Viral, Influenza A virus, Influenza B virus.
- immunology : Influenza A virus, Influenza B virus, Influenza, Human.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Adult, Aged, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Sentinel Surveillance, Young Adult.

Abstract

BACKGROUND

The 2014-2015 influenza season was distinguished by an epidemic of antigenically-drifted A(H3N2) viruses and vaccine components identical to 2013-2014. We report 2014-2015 vaccine effectiveness (VE) from Canada and explore contributing agent-host factors.

METHODS

VE against laboratory-confirmed influenza was derived using a test-negative design among outpatients with influenza-like illness. Sequencing identified amino acid mutations at key antigenic sites of the viral hemagglutinin protein.

RESULTS

Overall, 815/1930 (42%) patients tested influenza-positive: 590 (72%) influenza A and 226 (28%) influenza B. Most influenza A viruses with known subtype were A(H3N2) (570/577; 99%); 409/460 (89%) sequenced viruses belonged to genetic clade 3C.2a and 39/460 (8%) to clade 3C.3b. Dominant clade 3C.2a viruses bore the pivotal mutations F159Y (a cluster-transition position) and K160T (a predicted gain of glycosylation) compared to the mismatched clade 3C.1 vaccine. VE against A(H3N2) was -17% (95% confidence interval [CI], -50% to 9%) overall with clade-specific VE of -13% (95% CI, -51% to 15%) for clade 3C.2a but 52% (95% CI, -17% to 80%) for clade 3C.3b. VE against A(H3N2) was 53% (95% CI, 10% to 75%) for patients vaccinated in 2014-2015 only, significantly lower at -32% (95% CI, -75% to 0%) if also vaccinated in 2013-2014 and -54% (95% CI, -108% to -14%) if vaccinated each year since 2012-2013. VE against clade-mismatched B(Yamagata) viruses was 42% (95% CI, 10% to 62%) with less-pronounced reduction from prior vaccination compared to A(H3N2).

CONCLUSIONS

Variation in the viral genome and negative effects of serial vaccination likely contributed to poor influenza vaccine performance in 2014-2015.

DOI: 10.1093/cid/ciw176
PubMed: 27025838

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000149
to stream Main, to step Curation: 000149

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.</title>
<author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control.</nlm:affiliation>
<wicri:noCountry code="no comma">British Columbia Centre for Disease Control.</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>University of British Columbia, Vancouver.</nlm:affiliation>
<wicri:noCountry code="subField">Vancouver</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Chambers, Catharine" sort="Chambers, Catharine" uniqKey="Chambers C" first="Catharine" last="Chambers">Catharine Chambers</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control.</nlm:affiliation>
<wicri:noCountry code="no comma">British Columbia Centre for Disease Control.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Sabaiduc, Suzana" sort="Sabaiduc, Suzana" uniqKey="Sabaiduc S" first="Suzana" last="Sabaiduc">Suzana Sabaiduc</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control.</nlm:affiliation>
<wicri:noCountry code="no comma">British Columbia Centre for Disease Control.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name>
<affiliation><nlm:affiliation>Institut National de Santé Publique du Québec.</nlm:affiliation>
<wicri:noCountry code="no comma">Institut National de Santé Publique du Québec.</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Laval University.</nlm:affiliation>
<wicri:noCountry code="no comma">Laval University.</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Centre Hospitalier Universitaire de Québec.</nlm:affiliation>
<wicri:noCountry code="no comma">Centre Hospitalier Universitaire de Québec.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Winter, Anne Luise" sort="Winter, Anne Luise" uniqKey="Winter A" first="Anne-Luise" last="Winter">Anne-Luise Winter</name>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto.</nlm:affiliation>
<wicri:noCountry code="subField">Toronto</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Dickinson, James A" sort="Dickinson, James A" uniqKey="Dickinson J" first="James A" last="Dickinson">James A. Dickinson</name>
<affiliation><nlm:affiliation>University of Calgary.</nlm:affiliation>
<wicri:noCountry code="no comma">University of Calgary.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Krajden, Mel" sort="Krajden, Mel" uniqKey="Krajden M" first="Mel" last="Krajden">Mel Krajden</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control.</nlm:affiliation>
<wicri:noCountry code="no comma">British Columbia Centre for Disease Control.</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>University of British Columbia, Vancouver.</nlm:affiliation>
<wicri:noCountry code="subField">Vancouver</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gubbay, Jonathan B" sort="Gubbay, Jonathan B" uniqKey="Gubbay J" first="Jonathan B" last="Gubbay">Jonathan B. Gubbay</name>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto.</nlm:affiliation>
<wicri:noCountry code="subField">Toronto</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>University of Toronto.</nlm:affiliation>
<wicri:noCountry code="no comma">University of Toronto.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name>
<affiliation><nlm:affiliation>University of Alberta.</nlm:affiliation>
<wicri:noCountry code="no comma">University of Alberta.</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Alberta Provincial Laboratory, Edmonton.</nlm:affiliation>
<wicri:noCountry code="subField">Edmonton</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Martineau, Christine" sort="Martineau, Christine" uniqKey="Martineau C" first="Christine" last="Martineau">Christine Martineau</name>
<affiliation><nlm:affiliation>Institut National de Santé Publique du Québec.</nlm:affiliation>
<wicri:noCountry code="no comma">Institut National de Santé Publique du Québec.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Eshaghi, Alireza" sort="Eshaghi, Alireza" uniqKey="Eshaghi A" first="Alireza" last="Eshaghi">Alireza Eshaghi</name>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto.</nlm:affiliation>
<wicri:noCountry code="subField">Toronto</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control.</nlm:affiliation>
<wicri:noCountry code="no comma">British Columbia Centre for Disease Control.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
<affiliation><nlm:affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg.</nlm:affiliation>
<wicri:noCountry code="subField">Winnipeg</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<affiliation><nlm:affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg.</nlm:affiliation>
<wicri:noCountry code="subField">Winnipeg</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27025838</idno>
<idno type="pmid">27025838</idno>
<idno type="doi">10.1093/cid/ciw176</idno>
<idno type="wicri:Area/Main/Corpus">000149</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000149</idno>
<idno type="wicri:Area/Main/Curation">000149</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000149</idno>
<idno type="wicri:Area/Main/Exploration">000149</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.</title>
<author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control.</nlm:affiliation>
<wicri:noCountry code="no comma">British Columbia Centre for Disease Control.</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>University of British Columbia, Vancouver.</nlm:affiliation>
<wicri:noCountry code="subField">Vancouver</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Chambers, Catharine" sort="Chambers, Catharine" uniqKey="Chambers C" first="Catharine" last="Chambers">Catharine Chambers</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control.</nlm:affiliation>
<wicri:noCountry code="no comma">British Columbia Centre for Disease Control.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Sabaiduc, Suzana" sort="Sabaiduc, Suzana" uniqKey="Sabaiduc S" first="Suzana" last="Sabaiduc">Suzana Sabaiduc</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control.</nlm:affiliation>
<wicri:noCountry code="no comma">British Columbia Centre for Disease Control.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name>
<affiliation><nlm:affiliation>Institut National de Santé Publique du Québec.</nlm:affiliation>
<wicri:noCountry code="no comma">Institut National de Santé Publique du Québec.</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Laval University.</nlm:affiliation>
<wicri:noCountry code="no comma">Laval University.</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Centre Hospitalier Universitaire de Québec.</nlm:affiliation>
<wicri:noCountry code="no comma">Centre Hospitalier Universitaire de Québec.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Winter, Anne Luise" sort="Winter, Anne Luise" uniqKey="Winter A" first="Anne-Luise" last="Winter">Anne-Luise Winter</name>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto.</nlm:affiliation>
<wicri:noCountry code="subField">Toronto</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Dickinson, James A" sort="Dickinson, James A" uniqKey="Dickinson J" first="James A" last="Dickinson">James A. Dickinson</name>
<affiliation><nlm:affiliation>University of Calgary.</nlm:affiliation>
<wicri:noCountry code="no comma">University of Calgary.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Krajden, Mel" sort="Krajden, Mel" uniqKey="Krajden M" first="Mel" last="Krajden">Mel Krajden</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control.</nlm:affiliation>
<wicri:noCountry code="no comma">British Columbia Centre for Disease Control.</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>University of British Columbia, Vancouver.</nlm:affiliation>
<wicri:noCountry code="subField">Vancouver</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Gubbay, Jonathan B" sort="Gubbay, Jonathan B" uniqKey="Gubbay J" first="Jonathan B" last="Gubbay">Jonathan B. Gubbay</name>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto.</nlm:affiliation>
<wicri:noCountry code="subField">Toronto</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>University of Toronto.</nlm:affiliation>
<wicri:noCountry code="no comma">University of Toronto.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name>
<affiliation><nlm:affiliation>University of Alberta.</nlm:affiliation>
<wicri:noCountry code="no comma">University of Alberta.</wicri:noCountry>
</affiliation>
<affiliation><nlm:affiliation>Alberta Provincial Laboratory, Edmonton.</nlm:affiliation>
<wicri:noCountry code="subField">Edmonton</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Martineau, Christine" sort="Martineau, Christine" uniqKey="Martineau C" first="Christine" last="Martineau">Christine Martineau</name>
<affiliation><nlm:affiliation>Institut National de Santé Publique du Québec.</nlm:affiliation>
<wicri:noCountry code="no comma">Institut National de Santé Publique du Québec.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Eshaghi, Alireza" sort="Eshaghi, Alireza" uniqKey="Eshaghi A" first="Alireza" last="Eshaghi">Alireza Eshaghi</name>
<affiliation><nlm:affiliation>Public Health Ontario, Toronto.</nlm:affiliation>
<wicri:noCountry code="subField">Toronto</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name>
<affiliation><nlm:affiliation>British Columbia Centre for Disease Control.</nlm:affiliation>
<wicri:noCountry code="no comma">British Columbia Centre for Disease Control.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
<affiliation><nlm:affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg.</nlm:affiliation>
<wicri:noCountry code="subField">Winnipeg</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<affiliation><nlm:affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg.</nlm:affiliation>
<wicri:noCountry code="subField">Winnipeg</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series><title level="j">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</title>
<idno type="eISSN">1537-6591</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Canada (epidemiology)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Genome, Viral (genetics)</term>
<term>Humans</term>
<term>Infant</term>
<term>Influenza A virus (genetics)</term>
<term>Influenza A virus (immunology)</term>
<term>Influenza B virus (genetics)</term>
<term>Influenza B virus (immunology)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Sentinel Surveillance</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Canada (épidémiologie)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (immunologie)</term>
<term>Grippe humaine (virologie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Génome viral (génétique)</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Sujet âgé</term>
<term>Surveillance sentinelle</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Virus de la grippe A (génétique)</term>
<term>Virus de la grippe A (immunologie)</term>
<term>Virus influenza B (génétique)</term>
<term>Virus influenza B (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Canada</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Genome, Viral</term>
<term>Influenza A virus</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Génome viral</term>
<term>Virus de la grippe A</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Vaccins antigrippaux</term>
<term>Virus de la grippe A</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term>
<term>Influenza B virus</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Canada</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Infant</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Sentinel Surveillance</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Sujet âgé</term>
<term>Surveillance sentinelle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>The 2014-2015 influenza season was distinguished by an epidemic of antigenically-drifted A(H3N2) viruses and vaccine components identical to 2013-2014. We report 2014-2015 vaccine effectiveness (VE) from Canada and explore contributing agent-host factors.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>VE against laboratory-confirmed influenza was derived using a test-negative design among outpatients with influenza-like illness. Sequencing identified amino acid mutations at key antigenic sites of the viral hemagglutinin protein.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Overall, 815/1930 (42%) patients tested influenza-positive: 590 (72%) influenza A and 226 (28%) influenza B. Most influenza A viruses with known subtype were A(H3N2) (570/577; 99%); 409/460 (89%) sequenced viruses belonged to genetic clade 3C.2a and 39/460 (8%) to clade 3C.3b. Dominant clade 3C.2a viruses bore the pivotal mutations F159Y (a cluster-transition position) and K160T (a predicted gain of glycosylation) compared to the mismatched clade 3C.1 vaccine. VE against A(H3N2) was -17% (95% confidence interval [CI], -50% to 9%) overall with clade-specific VE of -13% (95% CI, -51% to 15%) for clade 3C.2a but 52% (95% CI, -17% to 80%) for clade 3C.3b. VE against A(H3N2) was 53% (95% CI, 10% to 75%) for patients vaccinated in 2014-2015 only, significantly lower at -32% (95% CI, -75% to 0%) if also vaccinated in 2013-2014 and -54% (95% CI, -108% to -14%) if vaccinated each year since 2012-2013. VE against clade-mismatched B(Yamagata) viruses was 42% (95% CI, 10% to 62%) with less-pronounced reduction from prior vaccination compared to A(H3N2).</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Variation in the viral genome and negative effects of serial vaccination likely contributed to poor influenza vaccine performance in 2014-2015.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27025838</PMID>
<DateCompleted><Year>2017</Year>
<Month>10</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>06</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>63</Volume>
<Issue>1</Issue>
<PubDate><Year>2016</Year>
<Month>07</Month>
<Day>01</Day>
</PubDate>
</JournalIssue>
<Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title>
<ISOAbbreviation>Clin. Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.</ArticleTitle>
<Pagination><MedlinePgn>21-32</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciw176</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">The 2014-2015 influenza season was distinguished by an epidemic of antigenically-drifted A(H3N2) viruses and vaccine components identical to 2013-2014. We report 2014-2015 vaccine effectiveness (VE) from Canada and explore contributing agent-host factors.</AbstractText>
<AbstractText Label="METHODS">VE against laboratory-confirmed influenza was derived using a test-negative design among outpatients with influenza-like illness. Sequencing identified amino acid mutations at key antigenic sites of the viral hemagglutinin protein.</AbstractText>
<AbstractText Label="RESULTS">Overall, 815/1930 (42%) patients tested influenza-positive: 590 (72%) influenza A and 226 (28%) influenza B. Most influenza A viruses with known subtype were A(H3N2) (570/577; 99%); 409/460 (89%) sequenced viruses belonged to genetic clade 3C.2a and 39/460 (8%) to clade 3C.3b. Dominant clade 3C.2a viruses bore the pivotal mutations F159Y (a cluster-transition position) and K160T (a predicted gain of glycosylation) compared to the mismatched clade 3C.1 vaccine. VE against A(H3N2) was -17% (95% confidence interval [CI], -50% to 9%) overall with clade-specific VE of -13% (95% CI, -51% to 15%) for clade 3C.2a but 52% (95% CI, -17% to 80%) for clade 3C.3b. VE against A(H3N2) was 53% (95% CI, 10% to 75%) for patients vaccinated in 2014-2015 only, significantly lower at -32% (95% CI, -75% to 0%) if also vaccinated in 2013-2014 and -54% (95% CI, -108% to -14%) if vaccinated each year since 2012-2013. VE against clade-mismatched B(Yamagata) viruses was 42% (95% CI, 10% to 62%) with less-pronounced reduction from prior vaccination compared to A(H3N2).</AbstractText>
<AbstractText Label="CONCLUSIONS">Variation in the viral genome and negative effects of serial vaccination likely contributed to poor influenza vaccine performance in 2014-2015.</AbstractText>
<CopyrightInformation>© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skowronski</LastName>
<ForeName>Danuta M</ForeName>
<Initials>DM</Initials>
<AffiliationInfo><Affiliation>British Columbia Centre for Disease Control.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of British Columbia, Vancouver.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chambers</LastName>
<ForeName>Catharine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>British Columbia Centre for Disease Control.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sabaiduc</LastName>
<ForeName>Suzana</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>British Columbia Centre for Disease Control.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>De Serres</LastName>
<ForeName>Gaston</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Institut National de Santé Publique du Québec.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Laval University.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Québec.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Winter</LastName>
<ForeName>Anne-Luise</ForeName>
<Initials>AL</Initials>
<AffiliationInfo><Affiliation>Public Health Ontario, Toronto.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dickinson</LastName>
<ForeName>James A</ForeName>
<Initials>JA</Initials>
<AffiliationInfo><Affiliation>University of Calgary.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Krajden</LastName>
<ForeName>Mel</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>British Columbia Centre for Disease Control.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of British Columbia, Vancouver.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gubbay</LastName>
<ForeName>Jonathan B</ForeName>
<Initials>JB</Initials>
<AffiliationInfo><Affiliation>Public Health Ontario, Toronto.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University of Toronto.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Drews</LastName>
<ForeName>Steven J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo><Affiliation>University of Alberta.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Alberta Provincial Laboratory, Edmonton.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martineau</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Institut National de Santé Publique du Québec.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Eshaghi</LastName>
<ForeName>Alireza</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Public Health Ontario, Toronto.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kwindt</LastName>
<ForeName>Trijntje L</ForeName>
<Initials>TL</Initials>
<AffiliationInfo><Affiliation>British Columbia Centre for Disease Control.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bastien</LastName>
<ForeName>Nathalie</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>TPA-90193</GrantID>
<Agency>CIHR</Agency>
<Country>Canada</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>03</Month>
<Day>29</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Clin Infect Dis</MedlineTA>
<NlmUniqueID>9203213</NlmUniqueID>
<ISSNLinking>1058-4838</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N">Canada</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016679" MajorTopicYN="N">Genome, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009980" MajorTopicYN="Y">Influenza A virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="Y">Influenza B virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018571" MajorTopicYN="N">Sentinel Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">antigenic drift</Keyword>
<Keyword MajorTopicYN="Y">genomics</Keyword>
<Keyword MajorTopicYN="Y">influenza vaccines</Keyword>
<Keyword MajorTopicYN="Y">sentinel surveillance</Keyword>
<Keyword MajorTopicYN="Y">vaccine effectiveness</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>12</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2016</Year>
<Month>03</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>3</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>3</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>10</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27025838</ArticleId>
<ArticleId IdType="pii">ciw176</ArticleId>
<ArticleId IdType="doi">10.1093/cid/ciw176</ArticleId>
<ArticleId IdType="pmc">PMC4901864</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Clin Infect Dis. 2013 May;56(10):1363-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23413420</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2016 Aug;16(8):942-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27061888</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2016;21(7):pii=30139</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26924024</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2015;20(36):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26535911</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2015 Jan 29;20(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25655053</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2009 May 26;106(21):8701-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19439657</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1999 Dec 3;286(5446):1921-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10583948</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14001-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10570188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2003 Jul 1;31(13):3381-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12824332</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Jan 27;9(1):e86555</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24475142</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 May 15;211(10):1519-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25416812</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 Sep 1;212(5):726-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25784728</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2015 Jan 16;64(1):10-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25590680</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Med. 2010 Apr 06;7(4):e1000258</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20386731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):583-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26042650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Feb 10;34(7):981-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26813801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2010 Dec 15;51(12):1370-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21067351</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2013 Nov 22;342(6161):976-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24264991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2009 Dec 15;49(12):1801-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19911946</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2015 Jul 22;10(7):e0132195</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26200655</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Rep. 2015 Jul 7;12(1):1-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26119736</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Proteome Res. 2015 Sep 4;14(9):3957-69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26202417</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Vaccines. 2014 Dec;13(12):1571-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25348015</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2016 Jan 2;34(1):61-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26611200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2016;21(3):30112</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26836031</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2014 Feb;58(3):319-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24235265</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2011 Nov;128(5):e1084-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21987710</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2015 May 15;211(10):1529-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25406334</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2014 Nov 15;59(10):1375-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25270645</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Mar 25;9(3):e92153</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24667168</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010 Mar 10;5(3):e9490</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20224823</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2014 Mar 7;89(10):93-104</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24707514</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2015 Feb 05;20(5):21024</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25677052</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Expert Rev Anti Infect Ther. 2011 Jun;9(6):669-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21692672</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2012;7(7):e41895</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22848649</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2014 Mar 14;6(3):1294-316</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24638204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2012 Feb 1;54(3):381-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22100572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2003 Jan 8;289(2):179-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12517228</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2013 Nov 27;8(11):e80481</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24312225</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Bastien, Nathalie" sort="Bastien, Nathalie" uniqKey="Bastien N" first="Nathalie" last="Bastien">Nathalie Bastien</name>
<name sortKey="Chambers, Catharine" sort="Chambers, Catharine" uniqKey="Chambers C" first="Catharine" last="Chambers">Catharine Chambers</name>
<name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name>
<name sortKey="Dickinson, James A" sort="Dickinson, James A" uniqKey="Dickinson J" first="James A" last="Dickinson">James A. Dickinson</name>
<name sortKey="Drews, Steven J" sort="Drews, Steven J" uniqKey="Drews S" first="Steven J" last="Drews">Steven J. Drews</name>
<name sortKey="Eshaghi, Alireza" sort="Eshaghi, Alireza" uniqKey="Eshaghi A" first="Alireza" last="Eshaghi">Alireza Eshaghi</name>
<name sortKey="Gubbay, Jonathan B" sort="Gubbay, Jonathan B" uniqKey="Gubbay J" first="Jonathan B" last="Gubbay">Jonathan B. Gubbay</name>
<name sortKey="Krajden, Mel" sort="Krajden, Mel" uniqKey="Krajden M" first="Mel" last="Krajden">Mel Krajden</name>
<name sortKey="Kwindt, Trijntje L" sort="Kwindt, Trijntje L" uniqKey="Kwindt T" first="Trijntje L" last="Kwindt">Trijntje L. Kwindt</name>
<name sortKey="Li, Yan" sort="Li, Yan" uniqKey="Li Y" first="Yan" last="Li">Yan Li</name>
<name sortKey="Martineau, Christine" sort="Martineau, Christine" uniqKey="Martineau C" first="Christine" last="Martineau">Christine Martineau</name>
<name sortKey="Sabaiduc, Suzana" sort="Sabaiduc, Suzana" uniqKey="Sabaiduc S" first="Suzana" last="Sabaiduc">Suzana Sabaiduc</name>
<name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M" last="Skowronski">Danuta M. Skowronski</name>
<name sortKey="Winter, Anne Luise" sort="Winter, Anne Luise" uniqKey="Winter A" first="Anne-Luise" last="Winter">Anne-Luise Winter</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000169 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000169 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeCanadaV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27025838
   |texte=   A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27025838" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 13:36:58 2020. Site generation: Sat Sep 26 07:06:42 2020

	Corpus GrippeCanadaV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeCanadaV3

A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.

A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki